Investigational drug · Phase 2
GPC-100
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Multiple Myeloma.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "GPC-100"
First trial start
2023
Feb 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GPC-100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "GPC-100" as an intervention, largest first.
GPCR Therapeutics, Inc.Industry
NCT05561751 · 28 participants · Start Feb 13, 2023 · Primary completion Sep 30, 2025
Drug: GPC-100; Propranolol and 1 more · For: Multiple Myeloma
Sites: La Jolla, California; Gainesville, Florida; Indianapolis, Indiana · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- An Open-label, Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) in Combination with Propranolol and G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Multiple Myeloma Patients.
Aljawai YM, Shah G, Jeong AR, et al. · Transplant Cell Ther 2026
- Shear and flexural performance of reinforced geopolymer concrete beams cured under ambient and oven conditions with environmentally friendly waste steel tire wire additives.
Özklç YO, Çelik A, Aksoylu C, et al. · Sci Rep 2025
- Pharmacological characterization of a clinical candidate, TG-0054, a small molecule inverse agonist targeting CXCR4.
Pan KS, Wang Z, Pfeil C, et al. · Mol Pharmacol 2025
- Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC-100), a Novel C-X-C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects.
Sukhtankar DD, Chang LW, Tsai CY, et al. · Clin Pharmacol Drug Dev 2023
- GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol.
Sukhtankar DD, Fung JJ, Kim MN, et al. · PLoS One 2023
- Glycerol-preserved corneal tissue in emergency corneal transplantation: An alternative for fresh corneal tissue in COVID-19 crisis.
Gupta N, Dhasmana R, Maitreya A, et al. · Indian J Ophthalmol 2020
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.